Keyphrases
First-in-human Study
100%
Clinical PET
100%
Neuroendocrine Tumor
100%
64Cu-DOTATATE
100%
Somatostatin Receptor Imaging
44%
Diethylenetriaminepentaacetic Acid
22%
Lesion Detection
22%
Radiation Dose
22%
Positron
22%
Radioactivity Concentration
22%
Octreotide
22%
Organ System
11%
Total-body PET/CT
11%
Imaging Procedures
11%
First-in-human
11%
Clinical Follow-up
11%
Metastatic Site
11%
Injected Activity
11%
Additional Lesion
11%
High Spatial Resolution
11%
Early-stage Detection
11%
Reduced Radiation
11%
Scintigraphy
11%
Spatial Resolution
11%
Standardized Uptake Value
11%
Image Quality
11%
Dose Estimates
11%
Labeled Compounds
11%
Study Support
11%
Positron Emission Tomography-computed Tomography (PET-CT)
11%
Tumor-to-background Ratio
11%
Imaging Time
11%
Clinical Application
11%
Human Use
11%
Multiple Endocrine Neoplasia Type 1 (MEN1)
11%
Absorbed Radiation Dose
11%
DOTATATE PET
11%
Effective Dose
11%
Radioisotopes
11%
Intravenous Injection
11%
OLINDA
11%
Positron Emitters
11%
Clinical Performance
11%
PET Scan
11%
Somatostatin Receptor Ligands
11%
Routine Imaging
11%
Liver
11%
Imaging Agents
11%
Accelerated Imaging
11%
SPECT-CT
11%
Radiation Burden
11%
Additional Findings
11%
Medicine and Dentistry
Neuroendocrine Tumor
100%
Polyethylene Terephthalate
100%
Copper 64
100%
Human Study
100%
Somatostatin Receptor
55%
Pentetic Acid
22%
Indium 111
22%
Octreotide
22%
Neoplasm
11%
Single Photon Emission Computed Tomography-Computed Tomography
11%
Imaging Agent
11%
Positron Emission Tomography-Computed Tomography
11%
Whole Body PET
11%
Multiple Endocrine Neoplasia Type I
11%
Radioisotope
11%
positron emission tomographic scan
11%
Organ Systems
11%
Intravenous Drug Administration
11%
Scintigraphy
11%
Standardized Uptake Value
11%
Pharmacology, Toxicology and Pharmaceutical Science
Neuroendocrine Tumor
100%
Human Study
100%
Copper 64
100%
Polyethylene Terephthalate
100%
Somatostatin Receptor
55%
Indium 111
22%
Octreotide
22%
Pentetic Acid
22%
Neoplasm
11%
Radioisotope
11%